PARAMUS, NJ, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics (“Polaryx” or the “Company”) a clinical-stage biotechnology company dedicated to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders (“LSDs”), today announced that shares of the Company’s common stock have been approved for listing on the Nasdaq Capital Market (“Nasdaq”) under the ticker symbol “PLYX”. Shares of Polaryx common stock are expected to commence ...

AMENDMENT NO. 2 TO FORM S-1 REGISTRATION STATEMENT Under The Securities Act of 1933 ___________________________ Polaryx Therapeutics, Inc. (Exact name of registrant as specified in its charter) ___________________________ (State or other jurisdiction of incorporation or organization) As filed with the Securities and Exchange Commission on January 27, 2026 Registration No. 333-291681 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (Primary Standard Industrial Classification Code Numbe ...

As filed with the Securities and Exchange Commission on January 13, 2026 Registration No. 333-291681 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT Under The Securities Act of 1933 ___________________________ Polaryx Therapeutics, Inc. (Exact name of registrant as specified in its charter) ___________________________ (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Numbe ...

Donovan Jones is an IPO research specialist with 15 years of experience identifying opportunities for high quality IPOs.He also leads the investing group IPO Edge, which offers actionable information on growth stocks through first-look IPO filings, previews on upcoming IPOs, an IPO calendar for tracking what’s on the horizon, a database of U.S. IPOs, and a guide to IPO investing to walk you through the entire IPO lifecycle - from filing to listing to quiet period and lockup expiration dates. Learn moreAnaly ...

As filed with the Securities and Exchange Commission on November 20, 2025 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT Under The Securities Act of 1933 ___________________________ Polaryx Therapeutics, Inc. (Exact name of registrant as specified in its charter) ___________________________ (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) Nevada 2834 47-339365 ...